Step 4 — Our current treks
Making genomic test results actionable
Elevation Oncology applies all of its insights towards the development of targeted therapies for novel driver alterations with high unmet patient needs.
Our first summit: NRG1 fusions
Our first clinical trial, CRESTONE (pronounced CRESS-tone), is a Phase 2 study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion. The CRESTONE study is actively enrolling patients now.
LEARN MORE ABOUT Crestone
Apr 2021 | MANUSCRIPT
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions
Odintsov et al., Clinical Cancer Research 2021
Oct 2020 | VIRTUAL ORAL PRESENTATION
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center
Jan 2021 | TPS449 – Trials in Progress Virtual Poster Presentation
CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210)
Presenting Author: Johanna Bendell, MD; Sarah Cannon Research Institute